


# Product Data Sheet

## XCT790

<b>Cat. No.:</b>	B3238
<b>CAS No.:</b>	725247-18-7
<b>Formula:</b>	C23H13F9N4O3S
<b>M.Wt:</b>	596.42
<b>Synonyms:</b>	
<b>Target:</b>	Endocrinology and Hormones
<b>Pathway:</b>	Estrogen/progestogen Receptor
<b>Storage:</b>	Store at -20°C



## Solvent & Solubility

insoluble in H<sub>2</sub>O; ≥14.9 mg/mL in DMSO; insoluble in EtOH

In Vitro

Preparing Stock Solutions	Solvent	Mass		
		1mg	5mg	10mg
	<b>Concentration</b>			
	<b>1 mM</b>	1.6767 mL	8.3834 mL	16.7667 mL
	<b>5 mM</b>	0.3353 mL	1.6767 mL	3.3533 mL
	<b>10 mM</b>	0.1677 mL	0.8383 mL	1.6767 mL

Please refer to the solubility information to select the appropriate solvent.

## Biological Activity

Shortsummary

ERR $\alpha$  agonist

IC<sub>50</sub> & Target

### Cell Viability Assay

In Vitro

Cell Line:	The human mammary epithelial cell line MCF7, H295R adrenocortical cancer cell line
Preparation method:	The solubility of this compound in DMSO is limited. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

	Reacting conditions:	1, 5, 10 $\mu$ M for 1-48 h
	Applications:	XCT790 induced deactivation and proteasome degradation of estrogen receptor-related receptor- $\alpha$ (ERR $\alpha$ ). XCT790 potentiated the ICI182,780-induced ER $\alpha$ degradation [1]. Moreover, XCT790 inhibited the proliferation and blocked G1/S transition of H295R adrenocortical cancer cell line [2].
In Vivo	<b>Animal experiment</b>	
	Animal models:	H295R cell xenograft tumors model
	Dosage form:	2.5 mg/kg, every other day for 21 days;
	Applications:	XCT790 reduced established H295R cell xenograft tumors growth and decreased H295R cells proliferation in vivo.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

## Product Citations

See more customer validations on [www.apexbt.com](http://www.apexbt.com).

## References

1. Lanvin, O., Bianco, S., Kersual, N., Chalbos, D. and Vanacker, J. M. (2007) Potentiation of ICI182,780 (Fulvestrant)-induced estrogen receptor-alpha degradation by the estrogen receptor-related receptor-alpha inverse agonist XCT790. J Biol Chem. 282, 28328-28334
2. Casaburi, I., Avena, P., De Luca, A., Chimento, A., Sirianni, R., Malivindi, R., Rago, V., Fiorillo, M., Domanico, F., Campana, C., Cappello, A. R., Sotgia, F., Lisanti, M. P. and Pezzi, V. (2015) Estrogen related receptor alpha (ERRalpha) a promising target for the therapy of adrenocortical carcinoma (ACC). Oncotarget. 6, 25135-25148

## Caution

**FOR RESEARCH PURPOSES ONLY.**

**NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.**

Specific storage and handling information for each product is indicated on the product datasheet. Most APEX BIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



**APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

